Back to Authors

Rohl, Stephen D.

Mayo Clinic

Mayo Clinic

Citations 2

Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts
Rohl, Stephen D., Miller, James L. , Knauf, Jeffrey A. , Ryder, Mabel , Milosevic, Dragana , Netzel, Brian C., Grebe, Stefan K., Smallridge, Robert C., Copland, John A. , Marlow, Laura A. , Knauf, Jeffrey A , Fagin, James A. , Reddi, Honey V. , Ryder, Mabel

The Journal of Clinical Endocrinology & Metabolism | May 25, 2018 | Volume: 103 | Issue: 9 | Pages: 3169-3182

10.1210/jc.2017-01845 Get It

Abstract 1038: Regulation of cyclin A by FoxO3a drives proliferation in anaplastic thyroid carcinoma
Rohl, Stephen D., Störz, Peter , Smallridge, Robert C., Copland, John A. , Marlow, Laura A. , Roemeling, Christina A. Von , Zhang, Yilin , Cooper, Simon JR , Tun, Han W.

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 1038-1038

10.1158/1538-7445.am2011-1038 Get It

Abstract The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth and is negatively regulated by growth factors via phosphorylation and mislocalization from the nucleus to the cytoplasm. Here we show for the first time that FoxO3a is nuclear in anaplastic thyroid carcinoma (ATC) and it transcriptionally upregulates cyclin A thereby promoting tumor growth in human ATC cells. Silencing FoxO3a in ATC cell lines leads to down-regulation of cyclin A mRNA and protein while over-expression of FoxO3a leads to upregulation of cyclin A protein. Transient co-transfection of cyclin A promoter linked to luciferase with FoxO3a leads to enhanced luciferase activity, which can be ablated when mutating the FoxO3a site on the cyclin A promoter. This combined data implicates an entirely novel function for FoxO3a in modulating cancer progression by promoting cell cycle progression and tumor growth. ATC is a poorly differentiated carcinoma with average survival upon diagnosis of 3–4 months with 99% lethality, notably the most aggressive and deadliest cancers known. This data also suggest that any therapies under development to inactivate FOXO3a may be effective at blocking tumor expansion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1038. doi:10.1158/1538-7445.AM2011-1038